Recipharm buys into an India CMO; PCI rebrands;

> Contract drugmaker Recipharm is paying about $105 million for a majority stake of Indian manufacturer Nitin Lifesciences. News

> PCI, fresh off acquisitions of Penn Pharma and Biotec, has rebranded itself. Item

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.